XOMA Royalty

XOMA Royalty functions as a specialized biotech royalty aggregator, acquiring and monetizing payment rights from pre-commercial drug candidates and commercial therapies. Operating under a capital-efficient model, its partners bear R&D costs, enabling a lean infrastructure. The company actively manages a diverse and expanding portfolio of over 120 therapeutic assets.

The foundational XOMA Corporation was established on May 21, 1981, pioneering the nascent biotechnology sector. This extensive history underpins XOMA Royalty's current strategy, which leverages deep industry experience to aggregate valuable intellectual property. The firm effectively converts future royalty streams into immediate assets for its partners.

XOMA Royalty supports biotechnology companies, offering alternative financing and monetization pathways for drug pipelines. Its central vision delivers substantial shareholder value through the strategic growth of its comprehensive royalty license portfolio. The company consistently aims to enhance portfolio optionality and secure enduring revenue from successful therapies via innovative deal-making.